You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 8 VITAL II: validation of the cerebrotech visor system for the noninvasive detection of hemispheric bioimpedance asymmetry in acute ischemic stroke

Article Text

Article menu
Download PDFPDF
Late-Breaking Oral Abstracts
8 VITAL II: validation of the cerebrotech visor system for the noninvasive detection of hemispheric bioimpedance asymmetry in acute ischemic stroke
  1. C Kellner1,
  2. E Sauvageau2,
  3. K Snyder3,
  4. K Fargen4,
  5. A Arthur5,
  6. R Turner6,
  7. R Nogueira7,
  8. A Alexandrov8
  1. 1Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY
  2. 2Neurosurgery, Lyerly Neurosurgery, Jacksonville, FL
  3. 3Neurosurgery, 3University at Buffalo, Buffalo, NY
  4. 4Neurosurgery, Wake Forest University, New Winston-Salem, NC
  5. 5Neurosurgery, University of Tennessee Health Sciences Center and Semmes-Murphey Clinic, Memphis, TN
  6. 6Neurosurgery, Medical University of South Carolina, Charleston, SC
  7. 7Neurology, Emory University, Atlanta, GA
  8. 8Neurology, University of Tennessee Health Sciences Center and Semmes-Murphey Clinic, New York, TN

Abstract

Introduction Given the robust evidence supporting thrombectomy in the treatment of acute stroke, accurate triage of patients suffering severe stroke has become an imperative. We previously evaluated the Cerebrotech Visor System (Cerebrotech, Pleasanton, CA) in a derivation study and found that the device was able to detect severe stroke with a sensitivity of 93% and a specificity of 92%. Here we validate the use of a novel, portable, easy-to-use device for the detection of severe stroke in a population of patients presenting to the hospital as acute stroke codes.

Methods The Cerebrotech Visor System measures bioimpedance on each brain hemisphere separately making it sensitive to asymmetries, such as those caused by emergent large vessel occlusion (ELVO). We recently completed enrollment on a multicenter validation study of 140 adult patients presenting as acute stroke codes who were evaluated with this new technology. The presence or absence of Severe Stroke including ELVO is confirmed on neuroimaging including CT, MR, and/or angiography within 30 min of the scan.

Results The results of this study will be complete by late June and are planned to be presented.

Conclusion We will present the conclusions of a multicenter clinical trial evaluating a new hand-held non-invasive brain scanning device that has the potential to transform stroke triage.

Disclosures C. Kellner: 1; C; Siemens, Penumbra. E. Sauvageau: None. K. Snyder: None. K. Fargen: None. A. Arthur: 4; C; Cerebrotech. R. Turner: None. R. Nogueira: None. A. Alexandrov: None.

http://dx.doi.org/10.1136/heartjnl-2014-307109.260

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.